Report contents
At a glance
- Business model: Dexcom sells a wearable continuous glucose monitor: a transmitter bought once and a disposable sensor replaced every 7 to 14 days, so sensors carry the recurring economics. Payers fund most purchases, so coverage rules, clinical accuracy and wear duration set how durable that annuity is. Patient-level sensor retention is not disclosed, and Abbott's lower-cost FreeStyle Libre checks pricing.
- Financial quality: Earnings convert to cash, with FY2025 operating cash flow of $1.44 billion against $0.84 billion of net income, about 1.7x, and free cash flow of $1.08 billion. Dexcom cut combined debt to $0.04 billion by year-end 2025 and held $1.82 billion in cash and marketable securities at September 30, 2026, with the revolver undrawn. Receivables and inventory balances are no longer broken out.
Business model
Business model: recurring sensors carry the economics
Dexcom sells continuous glucose monitoring (CGM) systems for people with diabetes: a wearable sensor that measures glucose and sends readings to a receiver or phone. The business is a razor-and-blade: the durable transmitter is sold once, while the disposable sensor is replaced every 7 to 14 days. That replacement cycle makes sensors the recurring profit engine. Payers—private insurers, Medicare, and national health systems—cover most purchases; patients pay copays or out-of-pocket for over-the-counter products. The U.S. is the largest market, with expansion in Europe and Asia. Dexcom is a medical device manufacturer in an expansion stage, targeting double-digit revenue and cash flow growth, according to its May 2026 Investor Day presentation.
Sensor annuity drives the profit pool
Sensor revenue repeats as long as the patient wears the device. The profit pool therefore depends on the size of the installed base and the frequency of replacement. Longer wear time lowers the patient's cost per day but reduces the number of sensors sold per year. That tradeoff matters: if Dexcom extends wear from 10 to 15 days, revenue per patient falls unless it wins more patients or raises price. Clinical accuracy and wear duration are the main levers for keeping patients and payers on board. The company does not publish patient-level sensor retention, so the durability of the recurring revenue has to be inferred from total sensor revenue and new patient starts. A decline in retention would weaken the annuity even if new customer additions look healthy.
Payer coverage is the real gatekeeper
End users are people with type 1 diabetes, type 2 diabetes, and gestational diabetes. The company is pushing into type 2 patients who do not use insulin, a much larger pool. Payers control access. In the U.S., Medicare and commercial insurers set coverage rules; internationally, national health systems negotiate prices. The May 2026 Investor Day framed the strategy as "driving health and economic outcomes that unlock global markets." That is an acknowledgment that coverage, not consumer advertising, determines adoption. Dexcom's bargaining power with payers is limited by Abbott's FreeStyle Libre, a lower-cost alternative. The type 2 non-insulin population has less acute needs, and payers may question whether CGM is cost-effective for them. Clinical trials aim to show better outcomes that could support broader coverage. If payers restrict coverage to narrower groups or require step therapy, the type 2 opportunity narrows.
Competition: Abbott is the shadow
Abbott's FreeStyle Libre is the main competitor, and Medtronic also sells CGM systems. Dexcom has led on clinical accuracy and user experience. The 2026 Investor Day highlighted "clinical superiority and emphasis on the customer" as core strengths. But Abbott competes on price and scale, with a large international footprint. If Abbott's next-generation sensor matches Dexcom's accuracy, the premium may narrow. The value chain runs from Dexcom's manufacturing to distributors and direct sales. Dexcom controls its sensor technology and software, but it relies on third-party distributors in some markets. The test is whether Dexcom can hold a price premium. Public filings do not break out average selling prices by geography, so investors must watch gross margin and third-party market share data. A decline in gross margin while volumes grow would suggest discounting.
Expansion into type 2 and OTC is the growth vector
Dexcom's double-digit growth plan depends on expanding beyond type 1 diabetes. The company cited a mobile randomized controlled trial published in JAMA in 2021 and a type 2 non-insulin treated (NIT) trial readout at the ADA 2026 Scientific Sessions. These trials support label expansion and reimbursement. The over-the-counter Stelo product targets people with type 2 diabetes who do not use insulin, a segment that may pay out of pocket. That avoids payer gatekeepers but requires consumer marketing and retail distribution, capabilities that differ from Dexcom's traditional medical sales model. Execution risk is not just manufacturing; it is also building a new channel and proving that the product improves outcomes enough for payers to cover it.
What would overturn the main judgment
The main judgment is that Dexcom's recurring sensor annuity, supported by clinical superiority and expanding payer coverage, can sustain double-digit growth. The clearest falsifier would be a sustained slowdown in sensor revenue growth while the company is launching into type 2 and OTC markets. If new patient starts fail to offset competition from Abbott, or if payers limit coverage for non-insulin type 2 patients, the recurring revenue model would still exist but would grow slower than the company targets. The next 12 to 18 months of coverage decisions, trial readouts, and competitive launches will test whether the expansion is on track.
Questions worth following
- Can Dexcom sustain double-digit sensor revenue growth as it expands into type 2 diabetes?
Sensor revenue is the core profit engine. If growth slows despite the type 2 and OTC launches, the recurring annuity is weaker than the company's double-digit target implies, which would pressure margins and the premium multiple.
- Will payer coverage for type 2 non-insulin CGM expand enough to support growth?
Payers control access to the largest untapped patient pool. Broader coverage would expand the addressable market and support volume growth; restrictive policies would cap adoption and slow the type 2 rollout.
- Can Dexcom defend its CGM pricing against Abbott's FreeStyle Libre?
Abbott competes on price and scale. If Dexcom must discount to hold share, gross margin and cash flow would fall, weakening the premium that the market assigns to the recurring sensor stream.
Financial quality
Financial quality: cash conversion still supports earnings
Financial quality: Strong. DexCom’s earnings increasingly arrive as cash, and the company used 2025 to repay most of its borrowings. The main unresolved items are whether the gross-margin recovery can hold and whether the earlier slowdown in receivables turnover has continued.
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 Q2 (quarterly) | Assessment |
|---|---|---|---|---|---|---|---|
| Revenue (USD bn) | 2.45 | 2.91 | 3.62 | 4.03 | 4.66 | 1.31 | Strong |
| Gross margin (%) | 68.6 | 64.7 | 63.2 | 60.5 | 60.1 | 63.4 | Strong |
| Net margin (%) | 8.9 | 11.7 | 14.9 | 14.3 | 18.0 | 19.1 | Strong |
| ROE (%) | 11.2 | 16.3 | 25.8 | 27.6 | 34.6 | n/m | Exceptional |
| ROA (%) | 4.7 | 6.6 | 9.3 | 9.0 | 13.1 | n/m | Strong |
| Current ratio | 5.11 | 1.99 | 2.84 | 1.47 | Not disclosed | Not disclosed | Adequate |
| Liabilities / assets (%) | 58.6 | 60.5 | 67.0 | 67.6 | 56.6 | 59.3 | Adequate |
| Asset turnover | 0.53 | 0.56 | 0.62 | 0.63 | 0.73 | n/m | Adequate |
| Inventory turnover | 2.59 | 3.35 | 3.08 | 2.89 | Not disclosed | Not disclosed | Adequate |
| Receivables turnover | 5.18 | 3.87 | 4.16 | 3.99 | Not disclosed | Not disclosed | Adequate |
| Operating cash flow (USD bn) | 0.44 | 0.67 | 0.75 | 0.99 | 1.44 | 0.27 | Exceptional |
| Free cash flow (USD bn) | 0.05 | 0.30 | 0.51 | 0.63 | 1.08 | 0.18 | Strong |
FY2025 gross margin, net margin, ROE, ROA, liabilities/assets and asset turnover were derived from the reported income statement and balance sheet; the other ratios are as reported. The FY2026 Q2 column is a single quarter, not annualized.
Cash conversion: the clearest sign of earnings quality
DexCom’s cash generation has improved faster than its net income. Operating cash flow rose from $0.44 billion in 2021 to $1.44 billion in 2025, while net income grew from $0.22 billion to $0.84 billion. Operating cash flow covered net income by about 1.7x in both 2024 and 2025; in the latest quarter it was $0.27 billion against $0.25 billion of net income. Free cash flow reached $1.08 billion in 2025, up from $0.05 billion in 2021. That gives DexCom room to fund the $1.0 billion repurchase authorization announced with third-quarter 2026 results without new borrowing.
Gross margin: the recovery is real, but the cause is only partly visible
GAAP gross margin fell from 68.6% in 2021 to 60.1% in 2025. The filings do not separate price, mix, and manufacturing cost, so revenue growth alone cannot explain whether G7 launch costs, international mix, or pricing drove the compression. The recovery to 63.4% in Q2 2026 and 64.3% in Q3 2026, as Dexcom reported, suggests the trough was not permanent. The company’s full-year 2026 guidance of about 64% non-GAAP gross margin adds support, but quarterly mix shifts could still produce swings.
Balance sheet: debt was reduced before the buyback
Total liabilities fell from 67.6% of assets in 2024 to 56.6% at year-end 2025. Reported long-term and short-term debt dropped from $2.47 billion combined at Q2 2025 to $0.04 billion at year-end. Dexcom said its revolving credit facility remained undrawn at September 30, 2026, with $1.82 billion in cash, cash equivalents and marketable securities. That reduces refinancing risk. It also removes the financial leverage that previously amplified ROE, so future returns now depend more on operating margins and asset utilization.
What to watch: receivables and inventory lack current detail
Receivables turnover slowed from 5.2x in 2021 to 4.0x in 2024, adding roughly 20 days of sales. Net receivables grew from $0.75 billion in 2022 to $1.03 billion in 2024, faster than the 38% revenue growth over the same period. DexCom no longer shows net receivables in the later balance sheets, so the recent direction is not public. Inventory turnover also edged down from 3.3x in 2022 to 2.9x in 2024, and inventory grew faster than sales through 2024. That may reflect deliberate stocking for the G7 15-day rollout, but current inventory balances are not disclosed.
| Period | Revenue (USD bn) | Net income (USD bn) | Total assets (USD bn) | Total liabilities (USD bn) | Net PP&E | Operating cash flow (USD bn) | Cash (USD bn) | Gross margin (%) | Assessment | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 Q1 | 1.04 | 0.11 | 6.75 | 4.49 | Not disclosed | 0.18 | 0.91 | 56.9 | Adequate | Improving |
| FY2025 Q2 | 1.16 | 0.18 | 7.33 | 4.75 | Not disclosed | 0.30 | 1.16 | 59.5 | Adequate | Improving |
| FY2025 Q3 | 1.21 | 0.28 | 7.50 | 4.77 | Not disclosed | 0.66 | 1.84 | 60.3 | Strong | Improving |
| FY2025 Q4 | 1.26 | 0.27 | 6.34 | 3.59 | Not disclosed | 0.29 | 0.92 | 62.7 | Strong | Improving |
| FY2026 Q1 | 1.19 | 0.20 | 6.63 | 3.68 | Not disclosed | 0.53 | 1.12 | 63.0 | Strong | Stable |
| FY2026 Q2 | 1.31 | 0.25 | 6.46 | 3.83 | Not disclosed | 0.27 | 1.10 | 63.4 | Strong | Stable |
Questions worth following
- Can DexCom sustain its gross margin recovery above 64%?
The recovery from 60.1% in 2025 to 63.4% in Q2 2026 changed the profit trajectory. If the G7 15-day transition and scale efficiencies support mid-60s margins, operating income and returns improve. If pricing or mix reverses, the recovery stalls and guidance of about 64% non-GAAP becomes less credible.
- Will DexCom reverse the slowdown in receivables turnover?
Receivables turnover fell from 5.2x in 2021 to 4.0x in 2024, adding roughly 20 days of sales. Current filings no longer show net receivables, so the answer would clarify whether the slowdown was transition-related or a structural shift in channel and payer mix.
- Can DexCom fund its $1 billion buyback while expanding capacity?
The buyback returns cash to shareholders, but production capacity expansion may raise capital spending and inventory. If free cash flow cannot cover both, DexCom will have to scale back repurchases or add leverage.
Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.
Continue reading the full report
- Key risksWhat could break the investment case
- Valuation and margin of safetyWhat the current price assumes, and how much room for error it leaves
- SummaryOur overall judgement and what to watch next
Free to sign up · 20 research points · unlocking this report uses 10
20 points cover 2 full reports. No card needed.
Research reflects its generation date. Preview the first two modules.
More on DexCom Inc
DexCom Inc
Business, moat and key questions
Open company page